Longboard Pharmaceuticals Company Overview
About Longboard Pharmaceuticals
Longboard Pharmaceuticals (NASDAQ:LBPH) is a biopharmaceutical company dedicated to developing novel, transformative medicines for neurological diseases. With a focus on creating solutions that address unmet medical needs, their projects revolve around a diverse pipeline of drug candidates aimed at improving the lives of patients suffering from various central nervous system disorders. The objectives of Longboard include advancing these drug candidates through clinical development, ensuring rigorous scientific research, and striving for therapeutic breakthroughs that can offer meaningful benefits to patients and their families. Their commitment lies not just in developing drugs but in changing the landscape of neurological disease treatment.
Snapshot
Operations
Products and/or services of Longboard Pharmaceuticals
- LP352 is a next-generation, oral, selective serotonin 5-HT2C receptor superagonist being developed for severe neurologic conditions, including developmental and epileptic encephalopathies.
- LP143, a full agonist of the aryl hydrocarbon receptor, is aimed at addressing anti-inflammatory needs in CNS disorders.
- LP659, designed to modulate the sphingosine-1-phosphate receptor, is focused on treating central nervous system inflammatory diseases.
Longboard Pharmaceuticals executive team
- Mr. Kevin R. LindPresident, CEO, Secretary & Director
- Ms. Brandi L. Roberts CPA, M.B.A.Executive VP & CFO
- Dr. Randall E. Kaye M.D.Executive VP & Chief Medical Officer
- Mr. Chadwick J. Orevillo MPHExecutive VP & Head of Operations
- Mr. Steven W. Spector J.D.Executive VP, Head of Business Development & General Counsel